David Boyer
Directeur/Membre du Conseil chez InflammX Therapeutics, Inc.
Profil
David Boyer currently works as a Director at InflammX Therapeutics, Inc.
Postes actifs de David Boyer
| Sociétés | Poste | Début |
|---|---|---|
InflammX Therapeutics, Inc.
 InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | Commercial Services |